Compare Quest Diagnostics Inc (DGX) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs EPR Properties — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while EPR Properties trades at $61.2 (market cap $4.58B). The key difference: Quest Diagnostics Inc is far larger — about 5.7× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.22%). Which is the better fit depends on your goals.
| DGX | EPR | |
|---|---|---|
Market Cap | $26.21B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $238.50 | $64.32 |
52-Week Low | $173.49 | $48.71 |
Enterprise Value | $31.97B | $8.09B |
Dividend Yield | 1.45% | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
EPR Properties trades at $60.81, up 0.68% on the day, with a bearish technical signal but strong fundamentals including a 91.41% gross margin and recent Q2 2026 FFO beat. The company raised full-year guidance after deploying $440 million in investments at an 8.5% cap rate, signaling growth momentum. Dividend payments remain consistent at $0.31 monthly, supported by a conservative 65% AFFO payout ratio.
Outlook is mixed: analyst consensus is a Buy with a $65.30 target (7% upside), but technicals and some sentiment caution near-term. Key risks include theater exposure and rising interest rates. The stock offers a 6% yield with potential for dividend growth, balancing income and moderate appreciation prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
